EpiCept to Host Q&A Conference Call March 3 at 10 A.M. Eastern Time

EpiCept to Host Q&A Conference Call March 3 at 10 A.M. Eastern Time

    TARRYTOWN, N.Y.--(BUSINESS WIRE)--Feb. 29, 2008--Regulatory News:

    EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today
announced it will host an investment community conference call on
Monday, March 3, 2008 beginning at 10:00 a.m. Eastern time. This
conference call is being held subsequent to an EpiCept conference call
on Friday, February 29, 2008 to discuss the Company's fourth quarter
and full year 2007 financial and operating results, which owing to
technical difficulties prevented participants from asking questions.

    To participate in the live call on March 3, please dial (888)
634-0563 from the U.S. or Canada or (706) 645-6609 from international
locations (please reference access code 37790283). The conference call
will also be broadcast live on the Internet and may be accessed at
www.epicept.com. The web cast will be archived for 90 days.

    A telephone replay of the call will be available for seven days by
dialing (800) 642-1687 from the U.S. and Canada or (706) 645-9291 from
international locations (please reference reservation number
37790283).

    About EpiCept Corporation

    EpiCept is focused on unmet needs in the treatment of pain and
cancer. The Company's broad portfolio of pharmaceutical product
candidates includes several pain therapies in clinical development and
a lead oncology compound for AML with demonstrated efficacy in a Phase
III trial; a marketing authorization application for this compound is
approaching a decision in Europe. In addition, EpiCept's ASAP
technology, a proprietary live cell high-throughput caspase-3
screening technology, can efficiently identify new cancer drug
candidates and molecular targets that selectively induce apoptosis in
cancer cells. Two oncology drug candidates currently in clinical
development that were discovered using this technology have also been
shown to act as vascular disruption agents in a variety of solid
tumors.

    Forward-Looking Statements

    This news release and any oral statements made with respect to the
information contained in this news release, contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements include statements
which express plans, anticipation, intent, contingency, goals,
targets, future development and are otherwise not statements of
historical fact. These statements are based on EpiCept's current
expectations and are subject to risks and uncertainties that could
cause actual results or developments to be materially different from
historical results or from any future results expressed or implied by
such forward-looking statements. Factors that may cause actual results
or developments to differ materially include: the risk that Ceplene
will not receive regulatory approval or marketing authorization in the
EU or that any appeal of an adverse decision will not be successful,
the risk that Ceplene(R), if approved, will not achieve significant
commercial success, the risks associated with our need to raise
additional financing to continue to meet our capital needs and our
ability to continue as a going concern, the risk that Myriad's
development of Azixa will not be successful, the risk that Azixa(TM)
will not receive regulatory approval or achieve significant commercial
success, the risk that we will not receive any significant payments
under our agreement with Myriad, the risk that the development of our
other apoptosis product candidates will not be successful, the risk
that our ASAP technology will not yield any successful product
candidates, the risk that clinical trials for NP-1 or EPC 2407 will
not be successful, that NP-1 or EPC 2407 will not receive regulatory
approval or achieve significant commercial success, the risk that our
other product candidates that appeared promising in early research and
clinical trials do not demonstrate safety and/or efficacy in
larger-scale or later stage clinical trials, the risk that EpiCept
will not obtain approval to market any of its product candidates, the
risks associated with dependence upon key personnel, the risks
associated with reliance on collaborative partners and others for
further clinical trials, development, manufacturing and
commercialization of our product candidates; the cost, delays and
uncertainties associated with our scientific research, product
development, clinical trials and regulatory approval process; our
history of operating losses since our inception; competition;
litigation; risks associated with prior material weaknesses in our
internal controls; and risks associated with our ability to protect
our intellectual property. These factors and other material risks are
more fully discussed in EpiCept's periodic reports, including its
reports on Forms 8-K, 10-Q and 10-K and other filings with the U.S.
Securities and Exchange Commission. You are urged to carefully review
and consider the disclosures found in EpiCept's filings which are
available at www.sec.gov or at www.epicept.com. You are cautioned not
to place undue reliance on any forward-looking statements, any of
which could turn out to be wrong due to inaccurate assumptions,
unknown risks or uncertainties or other risk factors.

    EPCT-GEN

    *Azixa is a registered trademark of Myriad Genetics, Inc.

    CONTACT: EpiCept Corporation
             Robert W. Cook, 914-606-3500
             rcook@epicept.com
             Or
             Media:
             Feinstein Kean Healthcare
             Greg Kelley, 617-577-8110
             gregory.kelley@fkhealth.com
             Or
             Investors:
             Lippert/Heilshorn & Associates
             Kim Sutton Golodetz, 212-838-3777
             kgolodetz@lhai.com
             or
             Bruce Voss, 310-691-7100
             bvoss@lhai.com